Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s Prevnar 13 Is Approved For Older Children As Use In Adults Lags

Executive Summary

FDA approved use of the pneumococcal vaccine in children and adolescents aged six to 17 years; uptake in adults 50 and older has been impacted by the delay in getting an ACIP vote on treatment, which is expected later this year.


Related Content

Prevnar 13 Recommendation For Medicare Population May Be Short Lived
Vaccines Chess Game Continues With Baxter Sale To Pfizer
No Near-Term Separations For Pfizer, But Business Model Will “Evolve”


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts